Chilly-Mazarin, March 26th 2010 - Metabrain Research is a Partnering Research Organisation (PRO) expert in metabolic diseases orchestrating private & public research ventures. The launch of their website www.metabrainresearch.com this April is the opportunity to present an innovative business model based on a scientific concept connecting metabolic and neurodegenerative diseases.The PRO concept bears the hallmarks of biotechs, CROs and basic research centers. Like a biotech, Metabrain Research proposes innovative drug discovery programs that it aims to partner at early stages with companies able to carry-out clinical developments. Like a CRO, Metabrain has state-of-the art drug discovery capacities covering medicinal chemistry, biology and pharmacology. This aspect is particularly relevant to companies in the metabolic disease area, as many experimental models present at Metabrain are unique. Finally, Metabrain coordinates private/public research ventures and contributes to the valorization of academic research...
[...]
...About Metabrain Research
Metabrain Research was created in March 2009, upon the closure of a preclinical R&D centre belonging to Merck Serono, to provide an innovative & sustainable model of early stage drug discovery research.
Based near Paris, in France, Metabrain Research is a PRO of 31 employees, expert in metabolic disorders. It functions as a stand-alone drug discovery unit disposing of chemistry, biology and pharmacology capacities and interacting with biotech, pharma and academia.
Metabrain proposes collaborative exploratory research programs linking metabolic and neurodegenerative diseases. Its expertise in diabetes and obesity is also available for contract research... [PDF] Metabrain Research's Press Release -
